Flow cytometric analysis of MCF7 (Human breast adenocarcinoma epithelial cell, Left) / SK-BR-3 (Human breast adenocarcinoma epithelial cell, Right) labelling CD340 antibody at 1/400 dilution (0.5 μg) / (Red) compared with a Mouse IgG1, κ monoclonal IgG (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). Goat Anti - Mosue IgG Alexa Fluor® 488 was used as the secondary antibody.
Negative control: MCF7
Mouse Anti-Human CD340 Antibody (S-3018)
Mouse Anti-Human CD340 Antibody (S-3018)
Price:
Regular price
$100 USD
Regular price
Sale price
$100 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD340 |
| Synonyms | Receptor tyrosine-protein kinase erbB-2; Metastatic lymph node gene 19 protein (MLN 19); Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD340; HER2; MLN19; NEU; NGL; ERBB2 |
| Location | Cytoplasm, Nucleus, Endosome, Cell membrane |
| Accession | P04626 |
| Clone Number | S-3018 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | SK-BR-3 |
| Purification | Protein G |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1:200 | Hu |
Background
CD340, also termed HER2/ErbB2, is a 1,255-amino-acid, 185 kDa glycosylated type-I trans-membrane receptor tyrosine kinase that lacks its own ligand-binding domain yet serves as the dimerization partner of choice for the other epidermal growth-factor receptors; upon hetero-dimerization it triggers potent downstream signaling cascades (MAPK, PI3K–Akt, PLC-γ, STAT) that drive proliferation, survival and microtubule stabilization, is frequently amplified or over-expressed on the surface of breast, ovarian and other epithelial tumours, and is therefore a key therapeutic target for monoclonal antibodies such as trastuzumab and pertuzumab.
Picture
Picture
FC
